Ubrelvy (ubrogepant)

Buy Ubrelvy (ubrogepant)
What is Ubrelvy (ubrogepant) for?

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine headaches with or without aura.^[1]

It will not prevent migraine headache.^[1]

It is available in tablet form containing 50 mg or 100 mg ubrogepant.^[1]

How does Ubrelvy (ubrogepant) work?

Ubrogepant is a monoclonal antibody, a type of protein, that blocks the activity of the calcitonin gene-related peptide (CGRP) receptor. CGRP is a molecule that is involved in migraine attacks. When its levels go up, it triggers intense inflammation in the brain, causing migraine headaches.^[2] By blocking the CGRP receptor, ubrogepant can relieve pain experienced during attacks.^[3]

It works without causing constriction in the blood vessels, which some older treatments are known to do.^[4]

Where has Ubrelvy (ubrogepant) been approved?

Ubrelvy (ubrogepant) was approved for the acute treatment of adults with migraine by:

• The Food and Drug Administration (FDA), USA, on December 23, 2019.^[4]

It is the first and only CGRP receptor antagonist that can be taken orally for the treatment of migraine attacks.^[4]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Ubrelvy (ubrogepant) taken?

The standard dosage is:^[1]

• 50 mg or 100 mg taken orally, as needed
• A second dose may be administered at least 2 hours after the initial dose for pain relief.

The maximum dose in a 24 hour period is 200 mg.^[1]

Because there is a risk of drug interactions, this medicine should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).^[1]

The dose of Ubrelvy (ubrogepant) should be modified when it is used together with specific drugs and for patients with liver (hepatic) or kidney (renal) impairment.^[1]

Complete information about Ubrelvy (ubrogepant) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Ubrelvy (ubrogepant)?

Common adverse reactions

The most common side effects (1-10% of patients) listed in the prescribing information include:^[1]

• Nausea
• Tiredness (fatigue)
• Dry mouth

Use in a specific population

Ubrelvy (ubrogepant) can cause fetal harm when administered to a pregnant woman, it is advised to avoid pregnancies and breastfeeding.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Ubrelvy (ubrogepant) [PDF] Allergan, Dec 23, 2019

2. What to Know About the New Anti CGRP Migraine Treatment Options
American Migraine Foundation, last checked on Aug 20, 2020

3. Ubrogepant for the Treatment of Migraine
Dodick DW, New England Journal of Medicine, Dec 5, 2019

4. FDA approves new treatment for adults with migraine
FDA press release, Dec 23, 2019

For more information please visit our blog page “What is Ubrelvy?”